We turn
academic
ideas into
accessible
medicines.
Orfenix turns promising academic therapies into investable development programmes that can reach patients, with access and affordability built in from the start.
Promising science.
No clear path.
Patients wait.
Academic institutions are built to discover and validate new science. Taking a therapy further requires a different combination of capabilities: development planning, regulatory strategy, funding, governance, specialist partners and commercialisation.
What’s missing is the central link that connects it all.
DEVELOPMENT
Complex. Resource-
intensive. Uncertain.
intensive. Uncertain.
FUNDING
Hard to fund early.
High risk. Misaligned
incentives.
High risk. Misaligned
incentives.
SCIENCE
Strong ideas.
Promising data.
Promising data.
PRODUCTION
Manufacturing strategy.
Scale-up. Quality.
Scale-up. Quality.
THE GAP
No single actor
takes ownership
of the full path.
takes ownership
of the full path.
CLINICAL
Trial design. Evidence.
Operational execution.
Operational execution.
PATIENT ACCESS
Access and affordability
not built in.
Patients wait.
not built in.
Patients wait.
REGULATION
Lengthy. Unclear.
Hard to navigate.
Hard to navigate.
COMMERCIALIZATION
Market complexity.
Business model
challenges.
Business model
challenges.
We turn
academic
ideas into
accessible
medicines.
An integrated approach.
Every step connected.
Orfenix works alongside researchers and academic institutions to turn promising therapeutic opportunities into structured development programmes.
We bring together the capabilities, partners and capital required to progress a therapy, while considering sustainable patient access from the start.
1
Venture structure & strategic coordination
We create the structure around the programme, aligning academic stakeholders, governance, strategy and responsibilities.
2
Regulatory & clinical development
We define a pragmatic development pathway, bringing regulatory, clinical and specialist expertise together around the science.
3
Funding & aligned partnerships
We build funding pathways and bring together public, private and specialist partners needed to progress the programme.
4
Access built in from the start
We consider affordability and patient access alongside development and commercial viability, rather than addressing them only once a therapy reaches the market.
Connecting ideas from R&D to impact.
Orfenix brings together the organisations and people needed to move promising academic therapies forward.
Researchers
Move discoveries forward without becoming biotech entrepreneurs.
TTOs
Advance therapies that fall outside standard licensing and spin-out routes.
Investors
Turn scientific promise into structured development opportunities.
Development
Engage with coordinated, ready-to-execute programmes.
When our model fits
Orfenix is designed for academic therapies that need a structured route from scientific discovery to patient access.
QUESTION 1 OF 5
YOUR PROJECT FIT